What is BioSig Technologies Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. BioSig Technologies's interest expense for the
three
months ended in Sep. 2024 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.01 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. BioSig Technologies's Operating Income for the
three
months ended in Sep. 2024 was $ -2.95 Mil. BioSig Technologies's Interest Expense for the
three
months ended in Sep. 2024 was $ 0.00 Mil.
BioSig Technologies has no long-term debt (1).
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BioSig Technologies Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioSig Technologies (NAS:BSGM) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
BioSig Technologies's Interest Expense for the
three
months ended in Sep. 2024 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Sep. 2024 was $-2.95 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Sep. 2024 was $0.00 Mil.
BioSig Technologies's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as
| BioSig Technologies had no long-term debt (1). |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
BioSig Technologies Business Description
Traded in Other Exchanges
N/A
Address
55 Greens Farms Road, 1st Floor, Westport, CT, USA, 06880
BioSig Technologies Inc is a commercial-stage medical device company with an advanced digital signal processing technology platform to deliver insights to the treatment of cardiovascular arrhythmias. Through collaboration with physicians, experts, and healthcare leaders across the field of electrophysiology (EP), It is committed to addressing healthcare's biggest priorities saving time, saving costs, and saving lives. Its first product, the PURE EP System, is an FDA-cleared non-invasive class II device consisting of a unique combination of hardware and software designed to provide unprecedented signal clarity and precision for real-time visualization of intracardiac signals paving the way for personalized patient care.
Executives
| Kenneth L Londoner |
director, 10 percent owner |
10 RED COAT ROAD, WESTPORT CT 06880 |
| Steven J Buhaly |
officer: Chief Financial Officer |
1195 NW LOMPTON DRIVE, BEAVESTON OR 97006 |
| John Sieckhaus |
officer: Chief Operating Officer |
C/O BIOSIG TECHNOLOGIES, 55 GREENS FARMS ROAD, WESTPORT CT 06880 |
| Steve Chaussy |
officer: Chief Financial Officer |
9780 E AVE, HESPERIA CA 92345 |
| Patrick Joseph Gallagher |
director |
275 PLEASANT HILL RD., FLANDERS NJ 07836 |
| Gray Fleming |
officer: Chief Commercial Officer |
C/O BIOSIG TECHNOLOGIES, INC., 55 GREENS FARMS ROAD, WESTPORT CT 06880 |
| James L Klein |
director |
2300NE BROOKWOOD PKWY, HILLSBORO OR 97124 |
| Frederick Hrkac |
director |
C/O BIOSIG TECHNOLOGIES, 55 GREENS FARMS ROAD, WESTPORT CT 06880 |
| James J Barry |
director |
C/O INSPIREMD, INC., 4 MENORAT HAMAOR ST., TEL AVIV L3 6744832 |
| Jeffrey F Odonnell |
director |
126 ROSSMORE DRIVE, MALVERN PA 19355 |
| Anthony P. Zook |
director |
C/O VIVUS, INC., 351 EAST EVELYN AVENUE, MOUNTAIN VIEW CA 94041 |
| Jerome B Zeldis |
director |
8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258 |
| Martha Pease |
director |
33 SEAVIEW, MADISON CT 06443 |
| John M Kowalski |
officer: VP of Sales |
54 WILTON ROAD, 2ND FLOOR, WESTPORT CT 06880 |
| Samuel E Navarro |
director |
C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044 |
BioSig Technologies Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BSGM has been successfully added to your 